Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Max Eddy Max Eddy is a writer who has covered privacy and security — including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results